Evidence map›Paper›PMID 38044872›Full record

ArticleEmerging microbes & infections2024

One HA stalk topping multiple heads as a novel influenza vaccine.

Ping Zhou, Tianyi Qiu, Xiang Wang, Xi Yang, Hongyang Shi, Caihong Zhu, Weiqian Dai, Man Xing, Xiaoyan Zhang, Jianqing Xu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Message from Editor-in-Chief: Write a New Chapter ofInfectious diseases & immunity · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ping ZhouDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.
Tianyi QiuInstitute of Clinical Science, ZhongShan Hospital, Fudan University, Shanghai, People's Republic of China.
Xiang WangShanghai Public Health Clinical Center, Fudan University, Shanghai, People's Republic of China.
Xi YangShanghai Public Health Clinical Center, Fudan University, Shanghai, People's Republic of China.
Hongyang ShiDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.
Caihong ZhuShanghai Public Health Clinical Center, Fudan University, Shanghai, People's Republic of China.
Weiqian DaiDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.
Man XingDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.
Xiaoyan ZhangShanghai Public Health Clinical Center, Fudan University, Shanghai, People's Republic of China.
Jianqing XuShanghai Public Health Clinical Center, Fudan University, Shanghai, People's Republic of China.
Dongming ZhouDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.
Shanghai Public Health Clinical Center · CNTianjin Medical University · CNChinese Academy of Sciences · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classic chimeric hemagglutinin (cHA) was designed to induce immune responses against the conserved stalk domain of HA. However, it is unclear whether combining more than one HA head domain onto one stalk domain is immunogenic and further induce immune responses against influenza viruses. Here, we constructed numerous novel cHAs comprising two or three fuzed head domains from different subtypes grafted onto one stalk domain, designated as cH1-H3, cH1-H7, cH1-H3-H7, and cH1-H7-H3. The three-dimensional structures of these novel cHAs were modelled using bioinformatics simulations. Structural analysis showed that the intact neutralizing epitopes were exposed in cH1-H7 and were predicted to be immunogenic. The immunogenicity of the cHAs constructs was evaluated in mice using a chimpanzee adenoviral vector (AdC68) vaccine platform. The results demonstrated that cH1-H7 expressed by AdC68 (AdC68-cH1-H7) induced the production of high levels of binding antibodies, neutralizing antibodies, and hemagglutinin inhibition antibodies against homologous pandemic H1N1, drifted seasonal H1N1, and H7N9 virus. Moreover, vaccinated mice were fully protected from a lethal challenge with the aforementioned influenza viruses. Hence, cH1-H7 cHAs with potent immunogenicity might be a potential novel vaccine to provide protection against different subtypes of influenza virus.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHemagglutininsHumansMiceAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza Vaccinesadenoviral vectorChimeric hemagglutinin (cHA)head domaininfluenza virus vaccinestalk domain

Identifiers

PMID38044872
PMCPMC10810646
OpenAlexW4389307396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.